Introduction/Background Introduction of molecular classification of endometrial cancer (EC) in clinical practice led to search of further markers. Chemokines are a family of cytokines which play important role in inflammation in tumour microenvironment. Their role in EC development remains unclear.

Methodology The research included 97 patients of whom 49 were diagnosed with stage I-II EC and formed a study group. Control group consisted of patients who underwent a hysterectomy due to non-oncological indications. Following axes of chemokines and their receptors were selected to analysis through a literature research: CXCL12-CXCR4/CXCR7, CCL2-CCR2, CCL20-CCR6, CXCL10-CXCR3. Expression of genes encoding the molecules was assessed in endometrial tissue with real-time polymerase chain reaction (PCR). Chemokines which presented a significant differences in expression were additionally evaluated with immunohistochemistry, both in endometrial and stromal tissue using immunoreactive score (IRS). Received data was analysed with parametrical and non-parametrical tests followed by correlation analysis.

Results Molecular analysis in 36 patients revealed significantly increased expression of CXCL10 (p=0,01) and CCL20 (p=0,001) in the study group. The expression of CXCL12 was higher in the control group (p=0,01). Overexpression of CXCL10 in EC tissue was confirmed in immunohistochemistry (group of 77 patients, p=0,006) with positive correlation with molecular findings. Stromal expression of CXCL12 was higher in the control group (p=0,008), as well as both endometrial and stromal expression of CCL 20 (p=0,002, negative correlation with PCR results).

Conclusion The overexpression of CXCL10 in non-advanced EC was detected in molecular and pathological assessment. This might be considered favourable prognostic factor, as CXCL10 plays a role in limitation of neoplastic process in preceding studies on other malignancies. Inconsistent results of CCL20 expression in PCR and immunohistochemistry indicate a need of further research, preferably with inclusion of advanced EC cases. This considers also CXCL12 and other chemokines evaluated in the study.

Disclosures The study was funded by Medical University of Bialystok from Polish Ministry of Science and Education grant SUB/1/DN/19/004/1129